Landos Biopharma (NASDAQ:LABP) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Landos Biopharma (NASDAQ:LABP – Get Rating) issued its earnings results on Thursday. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02), MarketWatch Earnings reports.

Shares of LABP traded up $0.01 during trading hours on Friday, hitting $0.68. The stock had a trading volume of 195,826 shares, compared to its average volume of 120,036. Landos Biopharma has a 12-month low of $0.61 and a 12-month high of $16.17. The company’s fifty day simple moving average is $1.29 and its 200 day simple moving average is $4.19.

A number of research firms have recently commented on LABP. Zacks Investment Research raised shares of Landos Biopharma from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research note on Wednesday, April 6th. Jefferies Financial Group lowered shares of Landos Biopharma from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. Finally, Raymond James cut their target price on shares of Landos Biopharma from $24.00 to $9.00 and set an “outperform” rating on the stock in a research note on Friday, March 25th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Landos Biopharma currently has an average rating of “Buy” and a consensus target price of $21.75.

Hedge funds and other institutional investors have recently modified their holdings of the company. Morgan Stanley grew its position in shares of Landos Biopharma by 1,337.0% during the second quarter. Morgan Stanley now owns 6,912 shares of the company’s stock worth $81,000 after buying an additional 6,431 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Landos Biopharma by 382.6% in the second quarter. Wells Fargo & Company MN now owns 9,526 shares of the company’s stock worth $110,000 after purchasing an additional 7,552 shares during the period. Goldman Sachs Group Inc. bought a new position in Landos Biopharma during the 4th quarter valued at $84,000. Bank of America Corp DE raised its holdings in shares of Landos Biopharma by 2,001.3% in the 4th quarter. Bank of America Corp DE now owns 31,225 shares of the company’s stock worth $150,000 after purchasing an additional 29,739 shares in the last quarter. Finally, Walleye Trading LLC purchased a new stake in shares of Landos Biopharma during the fourth quarter valued at $208,000. 66.53% of the stock is owned by institutional investors.

Landos Biopharma Company Profile (Get Rating)

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA).

See Also